The American Pain Society recognizes pain as a more visible and categorized vital sign. Terminal illnesses and injuries are often accompanied by unbearable pain. Literature have reported the use of cannabis as an alternative therapy to opioid treatment of pain.
Neuropathic pain is characterized by chronic pain that is induced by the dysfunction of the somatosensory nervous system. It involves a series of neurobiological events such as unpleasant abnormal sensation (dysesthesia); an increased response to painful stimuli (hyperalgesia); and pain in response to stimuli. Peripheral neuropathic pain may arise from damage to the peripheral nerves (sensory, motor, or autonomic), which is generally observed in many patients with chronic conditions like cancer, AIDS, long standing diabetes, lumbar disc syndrome, herpes infection, traumatic spinal cord injury, multiple sclerosis, stroke, thoracotomy, herniorrhaphy, mastectomy and sternotomy.
Pain management is a great challenge for healthcare professionals as it impacts the day-to- day functionality of their patients. This in turn impacts the nations productivity. In 2012, it was estimated that the national cost of pain management ranged from nearly $560 billion to $635 billion. According to the Arthritis Foundation, since 1999 there has been a 22 percent increase in the number of women who attribute their disability to arthritis. A major disadvantage of using currently available drug therapies to treat chronic severe pain is that these opioid based drugs may lead to addiction and side effects like hallucinations, constipation, sedation, nausea, respiratory depression, and dysphoria.
Natrinol and Our Patent
Natrinol is our patented formulation for neuropathic pain that is based on a combination of tetrahydrocannabinol (THC), cannabidiol (CBD) and other natural ingredients.